Loading stock data…
GNLX
$2.85+0.11 (+4.01%)
After Hours$2.85+0.00 (+0.00%)· Last close May 4
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Genelux Corporation in the Healthcare sector is trading at $2.84. The stock is currently near its 52-week low of $2.25, remaining 25.5% below its 200-day moving average. Technical signals show neutral RSI of 60 and bullish MACD crossover, explaining why GNLX maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 60) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.85
Potential Upside
5%
Whystock Fair Value$2.99
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus6 analysts
Mean target$17.50+514.0%
Range$10.00 – $31.00
Fundamentals
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimul...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$113.81M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.46
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-278.46%
Volume
Today's trading volume
144,237
Recent News
Institutions along with retail investors who hold considerable shares inGenelux Corporation (NASDAQ:GNLX) come under pressure; lose 16% of holdings value
Key Insights The considerable ownership by retail investors in Genelux indicates that they collectively have a greater...
Is Genelux (NASDAQ:GNLX) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
3 Promising Penny Stocks With Market Caps Under $200M
Major indexes in the United States are experiencing mixed performances, with tech stocks rallying and bank stocks sliding following recent inflation data. In this context, penny stocks remain a compelling area of interest for investors looking for potential growth opportunities. Although the term 'penny stocks' may seem outdated, these smaller or newer companies can offer significant value when backed by strong financials. Let's explore several such penny stocks that stand out for their...
June 2025's Promising Penny Stocks For Savvy Investors
As the U.S. markets navigate a landscape marked by geopolitical tensions and fluctuating oil prices, investors are keenly observing shifts in major indices like the Dow Jones and S&P 500. For those interested in exploring beyond established giants, penny stocks—often representing smaller or emerging companies—remain an intriguing investment area despite their somewhat outdated moniker. By focusing on financially robust penny stocks, investors can uncover potential opportunities that balance...
Genelux Corporation (GNLX) Upgraded to Buy: Here's What You Should Know
Genelux Corporation (GNLX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).